Pharmafile Logo

Healthwatch England

- PMLiVE

UK and US agree on landmark pharma pricing tariff deal

US tariffs on UK-produced pharmaceuticals will remain at zero for three years

- PMLiVE

ViiV Healthcare receives NICE recommendation for HIV prevention therapy

The treatment is the first and only long-acting HIV prevention option available on the NHS in England and Wales

- PMLiVE

New National Commission launched to strengthen AI regulation

The Commission will unite healthcare leaders, regulators and technology experts to shape future AI governance

- PMLiVE

NHS programme to give head and neck cancer patients fast-track access to mRNA vaccine

More than 11,000 people are diagnosed with head and neck cancers every year in England

- PMLiVE

NICE recommends BeOne’s Brukinsa to treat mantle cell lymphoma on NHS

Approximately 600 people are affected by the form of non-Hodgkin lymphoma every year in the UK

- PMLiVE

UK government publishes 10 Year Health Plan for England to ‘reinvent’ NHS

The plan’s three overarching themes are hospital to community, analogue to digital and sickness to prevention

- PMLiVE

NHS patients to access Theramex’s endometriosis pill following NICE recommendation

The once-a-day drug has been recommended for patients with a history of previous medical or surgical treatment

- PMLiVE

AXON NAMES NEW PRESIDENT AND MANAGING PARTNER, TINA HAHN, AS RALPH SUTTON CHANGES LANE

April 30, 2025—Tina Hahn, who joined AXON in 2012 as Vice President, will now take on the role of AXON’s President and Managing Partner.

AXON

- PMLiVE

NHS programme to give melanoma patients fast-track access to skin cancer vaccine

The phase 2 study will evaluate Scancell's iSCIB1+ in patients with advanced unresectable melanoma

- PMLiVE

Prime minister unveils UK government’s plans to abolish NHS England

The move aims to cut waiting times and free up money for front-line services

- PMLiVE

World Kidney Day – Boehringer launches CKD initiative to tackle UK health inequalities

Approximately 10% of the UK population is affected by chronic kidney disease

- PMLiVE

UK access pathway launched to get new medicines to patients in ‘shortest time possible’

The ILAP offers drug developers a single platform to collaborate with the MHRA and HTA bodies

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links